January 07, 2025 – AUSTIN, Texas–(BUSINESS WIRE)
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, Jan. 15, 2025 at 9:00 a.m. PT (12:00 p.m. ET).
Presentation and Q&A with Management
Members of management will deliver a presentation and host a Q&A with the investment community at the conference.
Live Webcast
A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. This allows investors, analysts, and other stakeholders to tune in remotely and participate in the Q&A session.
Replay Availability
A replay of the event will be available shortly following the conference. This ensures that those who are unable to attend can still access the presentation and Q&A at a later time.
About Natera
Natera is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. The company aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
Accomplishments and Certifications
Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. The company operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California.
Global Reach and Expertise
With a presence in various regions around the world, Natera is well-positioned to address the growing demand for cell-free DNA testing. The company’s commitment to innovation and excellence has established it as a trusted leader in the field of genetic testing.
History of Innovation
Natera has made significant contributions to the advancement of genetic testing through its innovative products and services. Some notable achievements include:
- Development of innovative tests: Natera has developed several groundbreaking tests that have revolutionized the way healthcare professionals approach diagnosis and treatment.
- Collaborations with leading institutions: The company has partnered with top research institutions and hospitals to further understanding and implementation of cell-free DNA testing.
Investor Relations
For more information about Natera’s investor relations, please visit www.natera.com.
Media Inquiries
Lesley Bogdanow, VP of Corporate Communications at Natera, can be reached at pr@natera.com for media inquiries.
Contact Information
Mike Brophy, CFO at Natera, Inc., can be reached at 650-249-9090 or investor@natera.com for investor-related questions and concerns.
Sources
For more information about this press release, please visit the original article on Business Wire: https://www.businesswire.com/news/home/20250107036377/en/
